Drug intelligence / Profile preview

JS001sc + pemetrexed + platinum

Development stage: Unknown
Lead developer: Junshi Biosciences
Modality: Small Molecules
Administration: Subcutaneous, Intravenous

Overview

JS001sc + pemetrexed + platinum is a combination regimen used as first-line therapy for recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC). It combines the programmed death receptor-1 (PD-1) antibody toripalimab with the antifolate chemotherapy agent pemetrexed and a platinum-based chemotherapy agent (either carboplatin or cisplatin).

Other names: Toripalimab (for JS001/JS001sc)pemetrexedplatinum-based chemotherapy (carboplatin or cisplatin)

Targets

GART (GAR transformylase)TS (Thymidylate synthase)PDCD1 (Programmed cell death protein 1 receptor)DHFR (Dihydrofolate reductase)DNA

Beyond the preview

Go deeper on JS001sc + pemetrexed + platinum.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JS001sc + pemetrexed + platinum.

Explore the full profile